512 related articles for article (PubMed ID: 34413645)
1. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
2. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
4. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
6. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy.
Xiong K; Zhang Y; Wen Q; Luo J; Lu Y; Wu Z; Wang B; Chen Y; Zhao L; Fu S
Int J Pharm; 2020 Nov; 589():119875. PubMed ID: 32919003
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
[TBL] [Abstract][Full Text] [Related]
9. Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle.
Yang Y; Meng Y; Ye J; Xia X; Wang H; Li L; Dong W; Jin D; Liu Y
J Control Release; 2018 Oct; 287():103-120. PubMed ID: 30144476
[TBL] [Abstract][Full Text] [Related]
10. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
11. Stimuli-responsive heparin-drug conjugates co-assembled into stable nanomedicines for cancer therapy.
Fang Z; Lin L; Li Z; Gu L; Pan D; Li Y; Chen J; Ding H; Tian X; Gong Q; Luo K
Acta Biomater; 2023 Jul; 164():422-434. PubMed ID: 37088159
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.
Chen X; Zhang Y; Tang C; Tian C; Sun Q; Su Z; Xue L; Yin Y; Ju C; Zhang C
Int J Pharm; 2017 Aug; 529(1-2):102-115. PubMed ID: 28642204
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
14. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
[TBL] [Abstract][Full Text] [Related]
15. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
[TBL] [Abstract][Full Text] [Related]
16. pH and redox dual-responsive copolymer micelles with surface charge reversal for co-delivery of all-
Zhang Y; Peng L; Chu J; Zhang M; Sun L; Zhong B; Wu Q
Int J Nanomedicine; 2018; 13():6499-6515. PubMed ID: 30410335
[TBL] [Abstract][Full Text] [Related]
17. Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.
Qian J; Xu N; Zhou X; Shi K; Du Q; Yin X; Zhao Z
Int J Nanomedicine; 2019; 14():7431-7446. PubMed ID: 31686815
[TBL] [Abstract][Full Text] [Related]
18. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
19. VE-Albumin Core-Shell Nanoparticles for Paclitaxel Delivery to Treat MDR Breast Cancer.
Tang B; Qian Y; Gou Y; Cheng G; Fang G
Molecules; 2018 Oct; 23(11):. PubMed ID: 30366367
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rb1 stabilized and paclitaxel / protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor.
Lu L; Ao H; Fu J; Li M; Guo Y; Guo Y; Han M; Shi R; Wang X
Biomed Pharmacother; 2023 Jul; 163():114870. PubMed ID: 37187019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
